Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)

NCT05134441 is registered in ClinicalTrials.gov with Immunic AG as lead sponsor.

NCT NCT05134441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05134441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)
Lead sponsor
Immunic AG
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 18, 2021
Completion date
September 30, 2033
Enrollment
1,121 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis